Novo Nordisk Navigates Obesity Drug Market Challenges with UBT251
Novo Nordisk is facing headwinds in the competitive obesity drug market following a setback with its CagriSema drug and unexpected sales forecasts. However, promising data from a Phase 2 trial of its investigational triple-action therapy, UBT251, offers a potential path forward. This article examines the current challenges for Novo Nordisk and the potential of UBT251 to regain momentum.
CagriSema Setback and Market Competition
Recent clinical trial data revealed that Eli Lilly’s Zepbound demonstrated superior weight loss compared to Novo Nordisk’s CagriSema. In a Phase 3 study, Zepbound achieved an average weight loss of 25.5% over 84 weeks, while CagriSema resulted in 23% weight loss. Despite this, Novo Nordisk has submitted CagriSema for FDA approval, with a decision expected by the end of 2026, and plans a Phase 3 study with higher doses in the second half of 2026. The company emphasizes that CagriSema still demonstrated clinically relevant effects beyond GLP-1 therapies.
UBT251: A Potential Game Changer
Novo Nordisk is placing renewed focus on UBT251, a triple agonist targeting the GLP-1, GIP, and glucagon receptors. Phase 2 trial data from a study conducted in China showed that UBT251 led to a mean weight loss of up to 19.7% after 24 weeks of treatment. This rapid weight loss is attracting investor attention, particularly as a potential response to the growing dominance of Eli Lilly’s drugs in the GLP-1 market. While comparisons across trials are challenging, the speed of weight loss with UBT251 suggests potential for significant long-term efficacy.
Financial Pressures and Analyst Reactions
Novo Nordisk is currently experiencing financial pressures due to price reductions in the U.S. Through a “Most Favored Nation” (MFN) pricing model, impacting Wegovy and Ozempic sales. The loss of exclusive rights for semaglutide in some international markets and unfavorable reimbursement dynamics are contributing to a weaker outlook. The company forecasts a sales decline of 5% to 13% for 2026, significantly lower than many analysts anticipated.
These challenges have prompted analyst downgrades. Deutsche Bank downgraded Novo Nordisk to “Hold” and lowered its target price, citing CagriSema’s trial results. Goldman Sachs also reduced its 12-month target price, citing pricing pressures. However, Morgan Stanley raised its rating to “Equal-weight,” arguing that the recent sell-off presents a buying opportunity.
Pipeline Developments and Future Outlook
Beyond UBT251 and CagriSema, Novo Nordisk is advancing other pipeline projects, including Mim8 (hemophilia), etavopivat (sickle cell disease), and ziltivekimab (chronic kidney disease). Wegovy also recently received FDA approval for the treatment of non-cirrhotic MASH with moderate to advanced fibrosis. Novo Nordisk has also partnered with Vivtex for oral drug delivery technologies, with potential payments of up to $2.1 billion.
The company is currently undertaking a $2.37 billion share buyback program. A shareholder vote on continuing the program beyond March 2026 will grab place on March 26, 2026.
Investor Considerations
Novo Nordisk faces short-term challenges related to pricing and competition, but UBT251 and its broader pipeline offer potential for medium-term growth. Investors will be closely watching the company’s capital allocation strategy and pipeline developments at the upcoming shareholder meeting on March 26, 2026.